# Challenges in the Management of Silent Lactotroph Pituitary Adenoma

## TL;DR

This paper discusses the difficulties in diagnosing and treating a rare type of pituitary tumor called silent lactotroph adenoma, emphasizing the need for detailed imaging and multidisciplinary evaluation.

## Contribution

The paper presents a case highlighting diagnostic challenges and management complexities of silent lactotroph adenomas, emphasizing the importance of imaging and histopathology.

## Key findings

- Silent lactotroph adenomas can mimic nonfunctioning adenomas, leading to diagnostic uncertainty.
- Detailed imaging and histopathological analysis are crucial for accurate diagnosis and management.
- Standardized treatment protocols are lacking for residual or recurrent disease in these tumors.

## Abstract

Silent lactotroph pituitary adenomas are rare tumors that clinically resemble nonfunctioning macroadenomas but are identified histologically by prolactin immunoreactivity. We report a 29-year-old woman with progressive visual loss caused by a large sella–suprasellar mass compressing the optic chiasm and invading the cavernous sinus. Initial endocrine evaluation was unremarkable, and magnetic resonance imaging (MRI) suggested a nonfunctioning adenoma. She underwent urgent surgical decompression, and histology confirmed a sparsely granulated lactotroph adenoma. Despite significant residual tumor on postoperative MRI, dopamine agonist therapy was not initiated due to absent dopamine receptor type 2 staining and patient-specific factors. Retrospective imaging review revealed atypical features, including heterogeneous T2-weighted signal, mixed cystic-solid morphology, and fluid-attenuated inversion recovery–T2 mismatch. This is potentially indicative of a silent subtype. This case underscores the diagnostic challenges posed by silent lactotroph adenomas and highlights the role of detailed imaging interpretation, histopathological analysis, and multidisciplinary evaluation in guiding management, especially in the absence of standardized treatment protocols for residual or recurrent disease.